<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T05:47:33Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:10459.1/57176" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:10459.1/57176</identifier><datestamp>2024-12-05T22:36:29Z</datestamp><setSpec>com_2072_3622</setSpec><setSpec>col_2072_479130</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:DIDLInfo>
      <dcterms:created xmlns:dcterms="http://purl.org/dc/terms/" xsi:schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2024-12-05T22:36:29Z</dcterms:created>
   </d:DIDLInfo>
   <d:Item id="hdl_10459.1_57176">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:10459.1/57176</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Sustained activation of renal N-methyl-D-aspartate receptors decreases vitamin D synthesis: a possible role for glutamate on the onset of secondary HPT</dc:title>
               <dc:creator>Parisi Capdevila, Eva</dc:creator>
               <dc:creator>Bozic, Milica</dc:creator>
               <dc:creator>Ibarz Escuer, Mercedes</dc:creator>
               <dc:creator>Panizo García, Sara</dc:creator>
               <dc:creator>Valcheva, Petya</dc:creator>
               <dc:creator>Coll, Blai</dc:creator>
               <dc:creator>Fernández i Giráldez, Elvira</dc:creator>
               <dc:creator>Valdivielso Revilla, José Manuel</dc:creator>
               <dc:subject>Paratyroid hormone</dc:subject>
               <dc:subject>Mitogen- activated protein kinase</dc:subject>
               <dc:subject>Hyerparatyroidism</dc:subject>
               <dc:description>N-methyl-D-aspartate&#xd;
(NMDA) receptors (NMDAR) are tetrameric amino acid receptors&#xd;
that act as membrane calcium channels. The presence of the receptor&#xd;
has been detected in the principal organs responsible for calcium&#xd;
homeostasis (kidney, bone, and parathyroid gland), pointing to a&#xd;
possible role in mineral metabolism. The aim of this study was to test&#xd;
the effect of NMDAR activation in the kidney and on 1,25(OH)2D3&#xd;
synthesis. We determined the presence of NMDAR subunits in HK-2&#xd;
(human kidney cells) cells and proved its functionality. NMDA&#xd;
treatment for 4 days induced a decrease in 1 -hydroxylase levels and&#xd;
1,25(OH)2D3 synthesis through the activation of the MAPK/ERK&#xd;
pathway in HK-2 cells. In vivo administration of NMDA for 4 days&#xd;
also caused a decrease in blood 1,25(OH)2D3 levels in healthy animals&#xd;
and an increase in blood PTH levels. This increase in PTH induced a&#xd;
decrease in the urinary excretion of calcium and an increase in urinary&#xd;
excretion of phosphorous and sodium as well as in diuresis. Bone&#xd;
turnover markers also increased. Animals with 5/6 nephrectomy&#xd;
showed low levels of renal 1 -hydroxylase as well as high levels of&#xd;
renal glutamate compared with healthy animals. In conclusion,&#xd;
NMDAR activation in the kidney causes a decrease in 1,25(OH)2D3&#xd;
synthesis, which induces an increase on PTH synthesis and release. In&#xd;
animals with chronic kidney disease, high renal levels of glutamate&#xd;
could be involved in the downregulation of 1 -hydroxylase expression.</dc:description>
               <dc:description>This work was supported by FIS PI09/0299, FIS PI07/0427, and REDINREN&#xd;
(16/06).</dc:description>
               <dc:date>2024-12-05T22:36:29Z</dc:date>
               <dc:date>2024-12-05T22:36:29Z</dc:date>
               <dc:date>2016-06-09T08:29:39Z</dc:date>
               <dc:date>2025-01-01</dc:date>
               <dc:date>2010</dc:date>
               <dc:type>article</dc:type>
               <dc:type>publishedVersion</dc:type>
               <dc:identifier>http://hdl.handle.net/10459.1/57176</dc:identifier>
               <dc:relation>Reproducció del document publicat a https://doi.org/10.1152/ajpendo.00428.2010</dc:relation>
               <dc:relation>AJP- Endocrinology and Metabolism, 2010, vol. 299, núm. 5, p. E825-E831</dc:relation>
               <dc:rights>(c) American Physiological Society, 2010</dc:rights>
               <dc:rights>info:eu-repo/semantics/restrictedAccess</dc:rights>
               <dc:publisher>American Physiological Society</dc:publisher>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>